BRPI0915868A2 - derivados de 9-alfa-estratrieno como lligantes seletivos de er-beta para a prevenção e tratamento de câncer intestinal - Google Patents

derivados de 9-alfa-estratrieno como lligantes seletivos de er-beta para a prevenção e tratamento de câncer intestinal

Info

Publication number
BRPI0915868A2
BRPI0915868A2 BRPI0915868A BRPI0915868A BRPI0915868A2 BR PI0915868 A2 BRPI0915868 A2 BR PI0915868A2 BR PI0915868 A BRPI0915868 A BR PI0915868A BR PI0915868 A BRPI0915868 A BR PI0915868A BR PI0915868 A2 BRPI0915868 A2 BR PI0915868A2
Authority
BR
Brazil
Prior art keywords
stratriene
alpha
selective
prevention
derivatives
Prior art date
Application number
BRPI0915868A
Other languages
English (en)
Inventor
Heinrich Fritzemeier Karl
Diel Patrick
Hertrampf Torsten
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0915868A2 publication Critical patent/BRPI0915868A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BRPI0915868A 2008-07-11 2009-07-09 derivados de 9-alfa-estratrieno como lligantes seletivos de er-beta para a prevenção e tratamento de câncer intestinal BRPI0915868A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160239A EP2143432A1 (en) 2008-07-11 2008-07-11 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
US8033308P 2008-07-14 2008-07-14
PCT/EP2009/005097 WO2010003700A1 (en) 2008-07-11 2009-07-09 9-alpha estratriene derivatives as er-beta selective ligands for the prevention and treatment of intestinal cancer

Publications (1)

Publication Number Publication Date
BRPI0915868A2 true BRPI0915868A2 (pt) 2017-06-20

Family

ID=39745141

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915868A BRPI0915868A2 (pt) 2008-07-11 2009-07-09 derivados de 9-alfa-estratrieno como lligantes seletivos de er-beta para a prevenção e tratamento de câncer intestinal

Country Status (13)

Country Link
US (1) US20110178052A1 (pt)
EP (2) EP2143432A1 (pt)
JP (1) JP2011527302A (pt)
KR (1) KR20110028619A (pt)
CN (1) CN102088980A (pt)
AU (1) AU2009268302A1 (pt)
BR (1) BRPI0915868A2 (pt)
CA (1) CA2730591A1 (pt)
IL (1) IL210223A0 (pt)
MX (1) MX2011000431A (pt)
RU (1) RU2011104569A (pt)
WO (1) WO2010003700A1 (pt)
ZA (1) ZA201101106B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2932224A1 (en) 2013-12-05 2015-06-11 Karo Pharma Ab Estrogen receptor beta agonists for use in treating mesothelioma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
HUP0300335A2 (hu) 2000-04-12 2003-07-28 Schering Ag. 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE10226326A1 (de) 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
DK1689410T3 (da) * 2003-11-26 2008-09-08 Bayer Schering Pharma Ag Forebyggelse og behandling af hypertensive hjertesygdomme ved de selektive östrogener 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol og 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
DE102005057224A1 (de) 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
EP2318009A1 (en) 2011-05-11
JP2011527302A (ja) 2011-10-27
CA2730591A1 (en) 2010-01-14
CN102088980A (zh) 2011-06-08
KR20110028619A (ko) 2011-03-21
RU2011104569A (ru) 2012-08-20
WO2010003700A1 (en) 2010-01-14
EP2143432A1 (en) 2010-01-13
IL210223A0 (en) 2011-03-31
ZA201101106B (en) 2012-07-25
MX2011000431A (es) 2011-05-19
AU2009268302A1 (en) 2010-01-14
US20110178052A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
BRPI0810206A2 (pt) Método de tratar câncer
LT3192529T (lt) Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
BRPI1016199A2 (pt) cobertura de ferimento e kit de tratamento de ferimentos.
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BR112012005594A2 (pt) tratamento de câncer
BRPI0923912A2 (pt) aparelho de cateter.
DK2121139T3 (da) Formulations for cancer treatment
BRPI0911579A2 (pt) dispositivo seguro para perfuração de tecido.
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
BRPI0813513A2 (pt) Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer
BR112012003372A2 (pt) vitamina d3 e análogos da mesma para o tratamento de alopecia.
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI1012155A2 (pt) cateter de segurança.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
DK2147122T3 (da) Enzymatisk kræftbehandling
BRPI0921407A2 (pt) terapia de combinação seletiva de erbb-3 (her3)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]